EVELINE PAUL: Open Payments
NPI 1154097095 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$389 in 20 payments from 12 companies in 2025. Trend: 2023 $303 · 2024 $248 · 2025 $389
Food & beverage: $389
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $76 |
| Novo Nordisk Inc | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| PFIZER INC. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Abbott Laboratories | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
Products named: MOUNJARO, XIFAXAN, Ozempic, JARDIANCE, GEMTESA, FREESTYLE LIBRE 3, ELIQUIS, Dexcom G6 Transmitter.
Industry payments across SC — which companies pay providers there.
